GT BIOPHARMA, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
GT BIOPHARMA, INC. (GTBP) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $2.81 per share for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-01.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2023-11-01
- GT BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.75.
- GT BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2020-03-31 was $0.00.
- GT BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $2.48.
- GT BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- GT BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2019 was $17340.00, a 1600.00% increase from fiscal 2018.
- GT BIOPHARMA, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2018 was $1020.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2023-09-30 | $2.81 10-Q · filed 2023-11-01 | ||||
| 2023-06-30 | $2.81 10-Q · filed 2023-08-07 | ||||
| 2023-03-31 | $2.75 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | $2.48 10-K · filed 2023-03-30 | ||||
| 2020-12-31 | $0.00 10-K · filed 2021-04-16 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-13 | ||||
| 2020-06-30 | $0.00 10-Q/A · filed 2020-08-18 | ||||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-15 | ||||
| 2019-12-31 | $17340.00 10-K · filed 2021-04-16 | $1500.00 10-K · filed 2020-03-27 | |||
| 2018-12-31 | $1020.00 10-K · filed 2020-03-27 | ||||
| 2017-12-31 | $0.00 10-K · filed 2019-03-29 | ||||
| 2016-12-31 | $16881.00 10-K · filed 2018-03-01 | ||||
| 2012-12-31 | $0.17 10-K · filed 2014-11-18 | ||||
| 2012-09-30 | $0.17 10-Q · filed 2012-11-21 | ||||
| 2012-06-30 | $0.17 10-Q/A · filed 2012-09-13 | ||||
| 2011-12-31 | $0.17 10-K · filed 2014-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |